Skip to content
Screener

Olema Pharmaceuticals, Inc. OLMA Financing Cash Flow

Financing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
$8.43B+777%
LON
LeonaBio, Inc.LONA
$82.44M+242,362%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$61.14M+555,718%
Opko Health logo
Opko HealthOPK
-$13.03M+83.6%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$84.33M+6,037%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$1.18M-95.5%

Other financials

Income statement

See full
Operating income-$58.0M-66.3%
Net income-$53.1M-74.7%
EPS (diluted)-$0.52-44.4%

Balance sheet

See full
Cash & equivalents$52.5M+3.8%
Total debt$956.0K-16.7%
Total equity$480.5M+25.3%
Total assets$530.6M+29.5%

Cash flow

See full
Operating cash flow-$46.0M-4.6%
CapEx-—
Free cash flow-$34.5M-27.8%

Valuation

See full
Market cap$1.03B+202%
Enterprise value$979.11M+238%

Returns & leverage

See full
Return on equity-42.9%+1.3pp
Debt / equity0×0.0×
Current ratio10.9×-4.3×

Where this comes from

Reported directly by Olema Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Olema Pharmaceuticals, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 7:10 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-218156
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Issuance costs for shares issued under private placement—(14)
Proceeds from exercise of stock options8,430236
Tax withholding for stock options exercised(4,407)—
Net cash provided by financing activities45,704222
Net increase (decrease) in cash and cash equivalents4,246(88,840)
Cash and cash equivalents at beginning of period48,301139,480
Cash and cash equivalents at end of period$52,547$50,640
Supplemental disclosure of non-cash financing activity

Item 1. Financial Statements.

FAQ

What is Olema Pharmaceuticals, Inc.'s financing cash flow?
Olema Pharmaceuticals, Inc. (OLMA) reported financing cash flow of $45.7M in Q1 2026.
How has Olema Pharmaceuticals, Inc.'s financing cash flow changed year-over-year?
Olema Pharmaceuticals, Inc.'s financing cash flow increased by 20487.4% year-over-year, from $222K to $45.7M.
What is the long-term trend for Olema Pharmaceuticals, Inc.'s financing cash flow?
Over 3 years (2022 to 2025), Olema Pharmaceuticals, Inc.'s financing cash flow has grown at a 662.8% compound annual growth rate (CAGR), from $476K to $211.3M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Olema Pharmaceuticals, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude